AZ's Lynparza Gets Prostate Cancer Priority Review
Hot On The Heels Of Clovis PARP Inhibitor Rubraca
Executive Summary
The race is firmly on to be the first PARP inhibitor approved for metastatic castration-resistant prostate cancer, with the FDA giving a speedy review to AstraZeneca and Merck & Co's Lynparza just days after granting the same to Clovis Oncology's Rubraca.